Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPCUN5)

• Drug Name: MT-110 Drug Info
• Synonyms: MuS110; Bispecific EpCAM/CD3 antibody (cancer), Micromet

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMPCUN5

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD3 gamma (CD3G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tebentafusp	DMUJ1WV	Gastric cancer	2B72	Approved	[2]
Teplizumab	DMZ3P6C	Type-1 diabetes	5A10	Approved	[3]
Ertumaxomab	DM5Z3VP	Breast cancer	2C60-2C65	Phase 2	[4]
MGD007	DMAHWLR	Colorectal cancer	2B91.Z	Phase 1/2	[5]
Autologous T-cell therapy	DMOAET3	Prostate cancer	2C82.0	Phase 1	[6]
MEDI-565	DMFWPLQ	Gastrointestinal cancer	2C11	Phase 1	[5]

Drug(s) Targeting Tumor-associated calcium signal transducer 1 (EPCAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vicineum	DMLO0KD	Bladder cancer	2C94	Phase 3	[7]
VB4-845	DMGKRAJ	Head and neck cancer	2D42	Phase 2/3	[8]
CAR-T Cells targeting EpCAM	DMREQCF	Colon cancer	2B90.Z	Phase 1/2	[9]
CAR-T Cells targeting EpCAM	DMREQCF	Colon cancer	2B90.Z	Phase 1/2	[10]
A-337	DMRWTFG	Non-small-cell lung cancer	2C25.Y	Phase 1	[11]
CAR-T cells recognizing EpCAM	DMC7Y5F	Breast cancer	2C60-2C65	Phase 1	[12]
ING-1	DM5WCBM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
Citatuzumab bogatox	DMRJF2Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
EPCAM-targeted CAR-T cells	DMV6RMB	Gastric adenocarcinoma	2B72	Clinical trial	[15]
IGN-101	DMOG1LX	Colorectal cancer	2B91.Z	Discontinued in Phase 2	[16]

Drug(s) Targeting T-cell surface glycoprotein CD3 epsilon (CD3E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Muromonab	DM8ANCF	Organ transplant rejection	NE84	Approved	[17]
Ertumaxomab	DM5Z3VP	Breast cancer	2C60-2C65	Phase 2	[4]
Resimmune	DMT5QSD	Cutaneous T-cell lymphoma	2B01	Phase 2	[18]
Autologous T-cell therapy	DMOAET3	Prostate cancer	2C82.0	Phase 1	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell surface glycoprotein CD3 epsilon (CD3E)	TTZAT79	CD3E_HUMAN	Not Available	[1]
T-cell surface glycoprotein CD3 gamma (CD3G)	TTV3XPL	CD3G_HUMAN	Not Available	[1]
Tumor-associated calcium signal transducer 1 (EPCAM)	TTZ8WH4	EPCAM_HUMAN	Not Available	[1]

References

• [1] EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
• [5] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [6] Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
• [7] Clinical pipeline report, company report or official report of Sesen Bio.
• [8] A bispecific EpCAM/CD133 targeted toxin is effective against carcinoma. Target Oncol. 2014 September; 9(3): 239-249.
• [9] ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
• [10] ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
• [11] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
• [12] ClinicalTrials.gov (NCT02915445) EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer
• [13] ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res. 2004 Nov 15;10(22):7555-65.
• [14] Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother Radiopharm. 2012 Nov;27(9):582-92.
• [15] ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer
• [16] Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer. Curr Opin Mol Ther. 2006 Aug;8(4):358-65.
• [17] Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35.
• [18] Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Haematologica.2015 Jun;100(6):794-800.